Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LNG115
MIFTS: 36

Lung Sarcomatoid Carcinoma

Categories: Cancer diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lung Sarcomatoid Carcinoma

About this section

MalaCards integrated aliases for Lung Sarcomatoid Carcinoma:

Name: Lung Sarcomatoid Carcinoma 12 17
Sarcomatoid Carcinoma of the Lung 12
Pulmonary Sarcomatoid Carcinoma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0080777
NCIt 50 C45540
Sources

Summaries for Lung Sarcomatoid Carcinoma

About this section
Disease Ontology : 12 A lung carcinoma that is characterized by the presence of a sarcomatoid component often associated with giant cell differentiation.

MalaCards based summary : Lung Sarcomatoid Carcinoma, also known as sarcomatoid carcinoma of the lung, is related to carcinosarcoma and pleomorphic carcinoma. An important gene associated with Lung Sarcomatoid Carcinoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways is Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics. The drugs Durvalumab and Mesna have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and skin.

Sources

Related Diseases for Lung Sarcomatoid Carcinoma

About this section

Diseases related to Lung Sarcomatoid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 162)
# Related Disease Score Top Affiliating Genes
1 carcinosarcoma 30.8 MUC1 CEACAM3 CALB2
2 pleomorphic carcinoma 30.8 NKX2-1 CALB2 ALK
3 benign mesothelioma 30.1 THBD NKX2-1 CALB2
4 asbestosis 30.1 THBD MUC1 CALB2
5 mucinous adenocarcinoma 30.0 NKX2-1 MUC1 ALK
6 small cell carcinoma 30.0 NKX2-1 MUC1 ALK
7 large cell neuroendocrine carcinoma 29.9 NKX2-1 ALK
8 sarcomatoid carcinoma 29.8 NKX2-1 NAPSA MUC1 KDM4C CALB2 ALK
9 adenosquamous carcinoma 29.8 NKX2-1 MUC4 MUC1
10 large cell carcinoma 29.8 NKX2-1 MUC1 CEACAM3
11 malignant pleural mesothelioma 29.4 THBD NKX2-1 MUC1 CALB2
12 adenocarcinoma 29.3 NKX2-1 NAPSA MUC4 MUC1 ALK
13 mesothelioma, malignant 29.2 THBD NKX2-1 MUC1 CEACAM3 CALB2
14 renal cell carcinoma, nonpapillary 29.1 NKX2-1 NAPSA MUC1 KDM4C CALB2
15 lung cancer susceptibility 3 28.8 NKX2-1 NAPSA MUC4 MUC1 CALB2 ALK
16 sarcomatoid mesothelioma 28.6 THBD NKX2-1 NAPSA MUC4 MUC1 CEACAM3
17 pulmonary blastoma 10.4
18 embryoma 10.4
19 fibrous histiocytoma 10.4
20 benign fibrous mesothelioma 10.3 CALB2 ALK
21 lung giant cell carcinoma 10.3
22 signet ring lung adenocarcinoma 10.3 EML4 ALK
23 malignant fibrous histiocytoma 10.3
24 fibrosarcoma 10.3
25 occipital lobe neoplasm 10.3 EML4 ALK
26 primary cutaneous anaplastic large cell lymphoma 10.3 MUC1 ALK
27 spindle cell thymoma 10.3 MUC1 CALB2
28 aggressive digital papillary adenocarcinoma 10.2 MUC1 CEACAM3
29 pediatric fibrosarcoma 10.2 EML4 ALK
30 sinonasal undifferentiated carcinoma 10.2 MUC1 CEACAM3
31 lung non-squamous non-small cell carcinoma 10.2 EML4 ALK
32 pancreatic mucinous cystadenoma 10.2 MUC1 CALB2
33 cystadenofibroma 10.2 MUC1 CALB2
34 pericardial mesothelioma 10.2 MUC1 CALB2
35 ovarian serous cystadenofibroma 10.2 MUC1 CALB2
36 endosalpingiosis 10.2 MUC1 CALB2
37 chondroid chordoma 10.2 MUC1 CEACAM3
38 autonomic nervous system benign neoplasm 10.2 KDM4C ALK
39 pericardium disease 10.2 CALB2 ALK
40 peripheral nervous system benign neoplasm 10.2 KDM4C ALK
41 apocrine adenocarcinoma 10.2 MUC1 CEACAM3
42 rhabdomyosarcoma 10.2
43 rare tumor 10.2
44 ovarian benign neoplasm 10.2 MUC1 CALB2
45 polymorphous low-grade adenocarcinoma 10.2 MUC1 CEACAM3
46 benign peritoneal mesothelioma 10.2 MUC1 CALB2
47 ovarian small cell carcinoma 10.2 MUC1 CALB2
48 bile duct adenoma 10.2 MUC1 CEACAM3
49 monophasic synovial sarcoma 10.2 MUC1 CALB2
50 hepatoid adenocarcinoma 10.2 MUC1 CEACAM3

Graphical network of the top 20 diseases related to Lung Sarcomatoid Carcinoma:



Diseases related to Lung Sarcomatoid Carcinoma
Sources

Symptoms & Phenotypes for Lung Sarcomatoid Carcinoma

About this section
Sources

Drugs & Therapeutics for Lung Sarcomatoid Carcinoma

About this section

Drugs for Lung Sarcomatoid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 18)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Durvalumab Approved, Investigational Phase 2 1428935-60-7
2
Mesna Approved, Investigational Phase 2 3375-50-6 598
3
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
4
Ifosfamide Approved Phase 2 3778-73-2 3690
5
Bevacizumab Approved, Investigational Phase 2 216974-75-3
6
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
7
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
8
Tremelimumab Investigational Phase 2 745013-59-6
9 Antibiotics, Antitubercular Phase 2
10
Isophosphamide mustard Phase 2 100427
11
Liposomal doxorubicin Phase 2 31703
12 Anti-Bacterial Agents Phase 2
13 Alkylating Agents Phase 2
14 Antineoplastic Agents, Immunological Phase 2
15 Angiogenesis Inhibitors Phase 2
16 Antimitotic Agents Phase 2
17 Albumin-Bound Paclitaxel Phase 2
18 Tubulin Modulators Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Phase II Study of Durvalumab + Tremelimumab in Pulmonary Sarcomatoid Carcinoma Unknown status NCT03022500 Phase 2 durvalumab + tremelimumab
2 A Phase II, Open-label Study to Evaluate the Efficacy and Safety of HMPL-504 in Locally Advanced/Metastatic MET-Mutation-Positive Pulmonary Sarcomatoid Carcinomas and Other Non-small Cell Lung Cancer Recruiting NCT02897479 Phase 2 Savolitinib
3 Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma Recruiting NCT04224337 Phase 2 Durvalumab + doxorubicin + ifosfamide
4 A Single-arm Exploratory Clinical Study on the Efficacy and Safety of Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma Not yet recruiting NCT04725448 Phase 2 Toripalimab;Bevacizumab;Nab-paclitaxel;Carboplatin
5 Integrative Analysis of Pulmonary Sarcomatoid Carcinoma (PSC) Not yet recruiting NCT04215913

Search NIH Clinical Center for Lung Sarcomatoid Carcinoma

Sources

Genetic Tests for Lung Sarcomatoid Carcinoma

About this section
Sources

Anatomical Context for Lung Sarcomatoid Carcinoma

About this section

MalaCards organs/tissues related to Lung Sarcomatoid Carcinoma:

40
Lung, Brain, Skin
Sources

Publications for Lung Sarcomatoid Carcinoma

About this section

Articles related to Lung Sarcomatoid Carcinoma:

(show top 50) (show all 82)
# Title Authors PMID Year
1
GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis. 61
33570661 2021
2
Strong ALK and PD-L1 positive IHC expression related ALK amplification in an advanced lung sarcomatoid carcinoma: A therapeutic trap? 61
33360808 2021
3
Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma. 61
31991225 2020
4
Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report. 61
32245391 2020
5
Paraneoplastic Hyperleukocytosis Mimicking Hematologic Malignancy Revealing a Localized Lung Cancer. 61
31408646 2020
6
Comprehensive Genomic Profiling of Rare Tumors: Routes to Targeted Therapies. 61
32373528 2020
7
Nkx2-4 Mutation Confers Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Sarcomatoid Carcinoma. 61
31122564 2019
8
Lazarus-type tumour response to therapy with nivolumab for sarcomatoid carcinomas of the lung. 61
31043837 2019
9
The Prognostic Significance Of JMJD3 In Primary Sarcomatoid Carcinoma Of The Lung, A Rare Subtype Of Lung Cancer. 61
31807019 2019
10
Postmortem Investigation of Immunohistochemical Staining and Gross Description of Sarcomatoid Carcinoma of the Lung in a Patient With Extreme Leukemoid Reaction. 61
31272237 2019
11
A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review. 61
31737389 2019
12
Efficacy of immunotherapy in sarcomatoid lung cancer, a case report and literature review. 61
30931249 2019
13
A clinical analysis of 114 cases of sarcomatoid carcinoma of the lung. 61
29987681 2018
14
Sarcomatoid Carcinoma of the Lung: The Mayo Clinic Experience in 127 Patients. 61
29454534 2018
15
The Hidden Genomic and Transcriptomic Plasticity of Giant Marker Chromosomes in Cancer. 61
29279323 2018
16
[Expression of anaplastic lymphoma kinase fusion gene in patients with lung sarcomatoid carcinoma and treatment analysis]. 61
29534405 2018
17
An anaplastic lymphoma kinase (ALK) fusion oncogene positive metastatic sarcomatoid carcinoma of the lung with good response to crizotinib. 61
30263998 2018
18
Sarcomatoid Carcinoma of the Lung Presenting as Localized Bronchiectasis: A Case Report and Review of Literature. 61
29984148 2018
19
CD8+ tumor-infiltrating lymphocytes as a novel prognostic biomarker in lung sarcomatoid carcinoma, a rare subtype of lung cancer. 61
30271199 2018
20
Overexpression of p53R2 is associated with poor prognosis in lung sarcomatoid carcinoma. 61
29246119 2017
21
GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung. 61
28614203 2017
22
A Rare Case of Sarcomatoid Carcinoma of the Lung with Spine Metastasis, Including a Literature Review. 61
28684728 2017
23
MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. 61
28418914 2017
24
MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma. 61
28128276 2017
25
Sarcomatoid carcinoma of the lung: a rare histological subtype of non-small cell lung cancer with a poor prognosis even at earlier tumour stages. 61
28025310 2017
26
Upper lip metastasis of sarcomatoid carcinoma of the lung - an unusual site of disease: a case report. 61
28100268 2017
27
PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis. 61
28671973 2017
28
Extreme leukocytosis and leukemoid reaction associated with the lung sarcomatoid carcinoma: an unusual case report. 61
28096688 2017
29
Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma. 61
27565934 2016
30
Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung. 61
27105684 2016
31
Primary Sarcomatoid Carcinoma of the Lung: Radiometabolic ((18)F-FDG PET/CT) Findings and Correlation with Clinico-Pathological and Survival Results. 61
27300448 2016
32
Lung Sarcomatoid Carcinoma Metastasis to Skin: A Case Report and Review of the Literature. 61
27348718 2016
33
An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma. 61
26281863 2016
34
[MET exon 14 mutation, new target in lung sarcomatoid carcinoma]. 61
27064153 2015
35
Sarcomatoid carcinoma of the lung mimics aspergilloma on ¹⁸F-FDG PET/CT. 61
26574699 2015
36
Gastrointestinal metastasis from primary sarcomatoid carcinoma of the lung: a case report and review of the literature. 61
25947890 2015
37
A three-gene signature and clinical outcome in esophageal squamous cell carcinoma. 61
25220908 2015
38
Sarcomatoid Carcinoma of the lung: A rare case of three small intestinal intussusceptions and literature review. 61
26111512 2015
39
Sarcomatoid carcinoma of the lung -  a case report. 61
25692756 2015
40
Primary sarcomatoid lung cancer: clinical and evolutive features: about five cases. 61
25867150 2014
41
Operative wound implantation of inflammatory sarcomatoid carcinoma of the lung. 61
25193203 2014
42
Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung. 61
24997135 2014
43
Sarcomatoid carcinoma of the lung: a model of resistance of chemotherapy. 61
25077084 2014
44
Extralobular sarcomatoid carcinoma of the lung. 61
24961191 2014
45
[Sarcomatoid carcinoma of the lung: retrospective study of 28 cases]. 61
24703022 2014
46
Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma. 61
24389441 2013
47
Sarcomatoid carcinoma of the lung with brain metastases. 61
24473771 2013
48
EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: a case report. 61
23664446 2013
49
Hypertrophic Pulmonary Osteoarthropathy: A Case Report. 61
29147313 2012
50
Outcomes of sarcomatoid carcinoma of the lung: a Surveillance, Epidemiology, and End Results Database analysis. 61
22739072 2012
Sources

Variations for Lung Sarcomatoid Carcinoma

About this section

Cosmic variations for Lung Sarcomatoid Carcinoma:

9 (show top 50) (show all 1782)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM102042323 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.-23-8009A>G p.? 16:72958974-72958974 9
2 COSM87291734 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 9
3 COSM102040476 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.-23-8037G>T p.? 16:72959002-72959002 9
4 COSM149314749 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 9
5 COSM87290218 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 9
6 COSM149318860 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 9
7 COSM126973051 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.770C>T p.P257L 11:102229729-102229729 9
8 COSM145028029 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1154C>T p.P385L 11:102229729-102229729 9
9 COSM128452039 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1142C>T p.P381L 11:102229729-102229729 9
10 COSM85237448 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1304C>T p.P435L 11:102229729-102229729 9
11 COSM143041512 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1316C>T p.P439L 11:102229729-102229729 9
12 COSM127997731 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1256C>T p.P419L 11:102229729-102229729 9
13 COSM133274224 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1268C>T p.P423L 11:102229729-102229729 9
14 COSM90948266 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1202C>T p.P401L 11:102229729-102229729 9
15 COSM108017622 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1009A>C p.I337L 22:41653558-41653558 9
16 COSM95166535 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 9
17 COSM97230831 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 9
18 COSM105839764 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1009A>C p.I337L 22:41653558-41653558 9
19 COSM106337415 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 9
20 COSM103711109 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1036A>C p.I346L 22:41653558-41653558 9
21 COSM85312404 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1207A>G p.M403V 19:43546970-43546970 9
22 COSM134125623 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1114A>G p.M372V 19:43546970-43546970 9
23 COSM100781761 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.724A>T p.K242* 11:32392044-32392044 9
24 COSM111539040 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1309A>T p.K437* 11:32392044-32392044 9
25 COSM149728755 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 9
26 COSM130518653 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.673A>T p.K225* 11:32392044-32392044 9
27 COSM113475703 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 9
28 COSM111529696 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 9
29 COSM113484991 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 9
30 COSM147414475 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 9
31 COSM149739953 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 9
32 COSM148580942 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 9
33 COSM148593279 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 9
34 COSM91372655 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 9
35 COSM91383011 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 9
36 COSM147426277 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1309A>T p.K437* 11:32392044-32392044 9
37 COSM124478343 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.422G>C p.G141A 5:138088927-138088927 9
38 COSM104050903 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.368G>C p.G123A 5:138088927-138088927 9
39 COSM105123686 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.*288A>C p.? 12:48966259-48966259 9
40 COSM87652733 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.1006A>C p.K336Q 12:48966259-48966259 9
41 COSM102763785 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.*288A>C p.? 12:48966259-48966259 9
42 COSM143166546 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.823G>T p.V275L 6:43777633-43777633 9
43 COSM144539293 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.823G>T p.V275L 6:43777633-43777633 9
44 COSM106394496 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.823G>T p.V275L 6:43777633-43777633 9
45 COSM112509623 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.283G>T p.V95L 6:43777633-43777633 9
46 COSM128143392 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.283G>T p.V95L 6:43777633-43777633 9
47 COSM97205442 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.283G>T p.V95L 6:43777633-43777633 9
48 COSM128342331 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.283G>T p.V95L 6:43777633-43777633 9
49 COSM142955742 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.823G>T p.V275L 6:43777633-43777633 9
50 COSM146194764 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.823G>T p.V275L 6:43777633-43777633 9
Sources

Expression for Lung Sarcomatoid Carcinoma

About this section
Search GEO for disease gene expression data for Lung Sarcomatoid Carcinoma.
Sources

Pathways for Lung Sarcomatoid Carcinoma

About this section

Pathways related to Lung Sarcomatoid Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics 60
10.2 EML4 ALK
Sources

GO Terms for Lung Sarcomatoid Carcinoma

About this section
Sources

Sources for Lung Sarcomatoid Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....